AVROBIO, Inc. logo

AVROBIO, Inc.

NASDAQ:AVRO

Overview | Financials
Company Name AVROBIO, Inc.
Symbol AVRO
Currency USD
Price 1.4
Market Cap 62,851,180
Dividend Yield 0%
52-week-range 0.88 - 1.65
Industry Biotechnology
Sector Healthcare
CEO Mr. Erik John Ostrowski M.B.A.
Website https://www.avrobio.com

An error occurred while fetching data.

About AVROBIO, Inc.

AVROBIO, Inc., a clinical-stage gene therapy company, develops ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose worldwide. Its gene therapies employ hematopoietic stem cells that are collected from patients and modified with a lentiviral vector to insert functional copies of the gene that is defective

Related Stocks

Tempest Therapeutics, Inc. logo

Tempest Therapeutics, Inc.

TPST

2.03 USD

Terns Pharmaceuticals, Inc. logo

Terns Pharmaceuticals, Inc.

TERN

7.23 USD

Biomerica, Inc. logo

Biomerica, Inc.

BMRA

0.448 USD

Oncternal Therapeutics, Inc. logo

Oncternal Therapeutics, Inc.

ONCT

8.18 USD

Evogene Ltd. logo

Evogene Ltd.

EVGN

0.633 USD

Moleculin Biotech, Inc. logo

Moleculin Biotech, Inc.

MBRX

3.74 USD

Corbus Pharmaceuticals Holdings, Inc. logo

Corbus Pharmaceuticals Holdings, Inc.

CRBP

42.48 USD

Financials

Numbers are in millions USD

Numbers are in millions USD